Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer
- Authors:
- Published online on: May 9, 2013 https://doi.org/10.3892/mco.2013.115
- Pages: 749-752
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Α pilot phase II study was conducted to evaluate the efficacy and safety of the combined administration of irinotecan (CPT‑11) plus cisplatin (CDDP) as a second‑line therapy for advanced or recurrent gastric cancer. Between November, 2006 and May, 2009, 18 patients were enrolled in this study. The patients were required to have received prior chemotherapy with S‑1 (n=17), an orally administered 5-fluorouracil (5-FU) prodrug, or S‑1 plus CDDP (n=1). CPT‑11 and CDDP were administered at a dose of 60 and 30 mg̸m2, respectively, on days 1 and 15 of a 4‑week treatment cycle. The regimen was repeated until the occurrence of unacceptable toxicity, disease progression, or patient refusal. The primary endpoint of this study was the response rate (RR). In the second‑line setting, 2 cases of complete response (CR), 1 of partial response (PR) and 7 of stable disease (SD) were identified. The RR was 16.7% and the disease control rate (DCR) was 55.6%. The median survival time (MST) and progression‑free survival (PFS) was 282 and 111 days, respectively. As regards hematological toxicity, the major adverse effect during the second‑line of chemotherapy was grade 3‑4 leukopenia (22.2%). In addition, with regard to non‑hematological toxicities, the major adverse effect during the second‑line chemotherapy was grade 3‑4 loss of appetite (11.1%). there was no mortality attributable to the adverse effects of the drugs. Findings of the present study suggested that CPT‑11 and CDDP combination therapy in a second‑line setting is an effective regimen in the treatment of advanced gastric cancer.
